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Over the past decade, next-generation sequencing (NGS) technology has experienced
meteoric growth in the aspects of platform, technology, and supporting bioinformatics
development allowing its widespread and rapid uptake in research settings. More recently,
NGS-based genomic data have been exploited to better understand disease development
and patient characteristics that influence response to a given therapeutic intervention. Can-
cer, as a disease characterized by and driven by the tumor genetic landscape, is particularly
amenable to NGS-based diagnostic (Dx) approaches. NGS-based technologies are particu-
larly well suited to studying cancer disease development, progression and emergence of
resistance, all key factors in the development of next-generation cancer Dxs.Yet, to achieve
the promise of NGS-based patient treatment, drug developers will need to overcome a
number of operational, technical, regulatory, and strategic challenges. Here, we provide a
succinct overview of the state of the clinical NGS field in terms of the available clinically
targeted platforms and sequencing technologies. We discuss the various operational and
practical aspects of clinical NGS testing that will facilitate or limit the uptake of such assays
in routine clinical care. We examine the current strategies for analytical validation and Food
and Drug Administration (FDA)-approval of NGS-based assays and ongoing efforts to stan-
dardize clinical NGS and build quality control standards for the same. The rapidly evolving
companion diagnostic (CDx) landscape for NGS-based assays will be reviewed, highlight-
ing the key areas of concern and suggesting strategies to mitigate risk. The review will
conclude with a series of strategic questions that face drug developers and a discussion
of the likely future course of NGS-based CDx development efforts.
Keywords: companion diagnostics, disruptive technology, precisionmedicine, next-generation sequencing, clinical
next-generation sequencing, molecular diagnostics, drug development strategy, mutation detection methods
INTRODUCTION
The concept of personalized medicine relies heavily on access to
information on an individual’s unique genetic characteristics to
tailor therapy. However, the current paradigm of regulated mole-
cular diagnostic (Dx) testing, in which individual Food and Drug
Administration (FDA)-cleared Dx tests are employed to detect
mutations in a single gene, sits uneasily in this framework of per-
sonalized medicine (1, 2). The advent of clinical next-generation
sequencing (NGS) has begun to provide to the clinic a more
Abbreviations: ABRF, Association of Biomolecular Resource Facilities; ACMG,
American College of Medical Genetics and Genomics; BRAF, v-Raf murine sar-
coma viral oncogene homolog B; CAP, College of American Pathologists; CDER,
Center for Drug Evaluation and Research; CDRH, Center for Devices and
Radiological Health; CDx, companion diagnostic; CE Conformité Européenne,
Conformity Marking for Relevant European Council Directives; CFTR, cystic
fibrosis transmembrane conductance regulator; CLIA, Clinical Lab Improve-
ment Amendment; CRO, contract research organization; CTA, clinical trial
assay; ddNTPs, dideoxynucleotide triphosphates; DNA, deoxyribonucleic acid;
dNTPs, deoxynucleotide triphosphates; Dx, diagnostic; EGFR, epidermal growth
factor receptor gene; EMR, electronic medical records; ePCR, emulsion PCR;
FDA, United States Food and Drug Administration; FFPE, formalin fixed
expansive insight into genetic mutations in a broader set of genes,
usually drawn from pathways implicated in and actionable by
current therapeutics or by promising drug candidates in develop-
ment (3). NGS-based diagnosis is specially promising for diseases
that have a highly complex and heterogeneous genetic composi-
tion. The field of oncology is therefore very well positioned to
benefit greatly from such an approach (4, 5). Since NGS-based
technology permits a more complete view into a tumor’s genetic
composition, it is easy to foresee that treatment paradigms must
paraffin embedded; gDNA, genomic DNA; IHC, immunohistochemistry; ISPs,
ion sphere particles; IUO, investigational use only; IVD, in vitro diagnostic;
KRAS, Kirsten rat sarcoma viral oncogene homolog gene; LDT, lab-developed
test; MAQC, microarray quality control; NCI, National Cancer Institute; NGS,
next-generation sequencing, NIST, National Institute of Standards and Tech-
nology; NTC, no template control; PacBio, Pacific Biosciences; PGM, Personal
Genome Machine; PMA, pre-market approval; PT, proficiency testing; QC, qual-
ity control; qPCR, quantitative polymerase chain reaction; RNA, ribonucleic
acid; RNA-Seq, RNA sequencing; RUO, research usage only; SMRT, single mol-
ecule real time sequencing; SNV, single nucleotide variant; TAT, turnaround
time; UTR, untranslated region; VCF, variant calling file; ZMW, zero-mode
waveguides.
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change accordingly to allow treatment based on the molecular
pathological fingerprint of the individual. As a result, the ques-
tion is not technological (“Can it be done?”), but rather practical
(“How can NGS technology be developed into a mainstream
multi-gene or multi-transcript Dx fingerprint?”) and regulative
(“What are the barriers that must be overcome for this disrup-
tive technology be approved as a general companion diagnostic
(CDx) device for multiple therapeutics?”). It is clear the scientific
community is rapidly embracing the technology as NGS-based
tests are being employed across multiple disease areas, including
oncological, metabolic, cardiovascular and neurosensory disor-
ders, and in prenatal diagnoses (6–10) where genetic components
are defined. As of late 2013, several dozen clinical labs offer over
50 different laboratory-developed tests (LDTs) using NGS (11).
These tests are offered as single-gene assays or multi-gene or multi-
transcript panels. Commercially available NGS-based cancer pan-
els are already being used in clinical practice and as clinical trial
assays (CTAs) to guide patients to most appropriate experimen-
tal treatment (8, 12, 13). Nonetheless, there are no FDA-approved
NGS CDxs available today and there are significant challenges in
developing such tests. We compare developing NGS-based Dx to
navigating the rapids, an exercise full of challenges, continuously
changing technologies, policies, and regulations as the field devel-
ops at a rapid pace, and yet the promise of personalized medicine
is within reach and closer than ever before.
CURRENT PARADIGM IS UNSUSTAINABLE
Precision medicine has been defined as identifying the right drug,
for the right patient, at the right dose, at the right time (14). Intrin-
sic to identifying the right patient is a Dx device. If it is linked to
a specific therapeutic and if the test is required for the safe and
effective use of the drug, then Dx device is termed a CDx. The cur-
rent testing paradigm for precision medicine links a specific drug
to the Dx (15, 16) and can be summarized as “one-drug/one-gene
Dx.” This is abundantly illustrated for FDA-approved Dxs, such
as the one-gene tests approved for mutations in EGFR, KRAS,
and BRAF. Yet, it is equally clear that the current paradigm is not
sustainable (17, 18). First, cancer is an exceedingly complex mol-
ecular and epigenomic disorder, resulting from perhaps hundreds
of different molecular defects, including somatic mutations, gene
expression changes, and genome rearrangements. Furthermore,
tumorigenesis and tumor progression are driven by altered gene
regulation networks that are not always tractable to a clear and
defined somatic mutation (19). Recent results from clinical stud-
ies support the emerging concept of the “mutation signature” or
spectrum of correlated mutations in cancer (20, 21), which postu-
lates that the combination of mutations present is more predictive
of the response to treatment than individual gene mutation status.
Thus, to ensure their patients are offered the best possible treat-
ment, physicians will want to examine the tumor’s whole cancer
genome, both somatic mutation and transcriptional changes, to
identify the most personalized therapy, and they will do so whether
or not there is a FDA-sanctioned Dx for a particular drug. Instead,
they will use LDTs, which the FDA believes should be regulated as
in vitro diagnostics (IVDs) (75 FR 34463, 2010). Thus, the current
situation is untenable since it is only a matter of time before more
comprehensive tests will routinely be used to diagnose a patient’s
tumor. Second, not only do physicians need more molecular infor-
mation, but patients want it too. In this age of internet medicine,
many patients are well-informed and strongly advocate for more
comprehensive testing, even to the point of paying for it themselves
in order to get a more complete picture of their cancer (22). Their
reasoning that more information is better is hard to argue against.
Hospitals and for-profit companies have developed tests to meet
this need, and advertisements for comprehensive genomic tumor
assessment on television, radio, and internet are not uncommon.
Furthermore, patients considering a clinical trial at a major hos-
pital are beginning to expect molecular characterization of their
tumor as a quid pro quo for participation in the clinical study. A
third, more practical, reason why the current model is not sus-
tainable is the limitation of tissue. A Dx tumor specimen block
can only be sectioned into a limited number of sections. Sample
is limiting and tests are not currently multiplexed; separate slides
are usually required for different immunohistochemical (IHC)-,
ribonucleic acid (RNA)-, or deoxyribonucleic acid (DNA)-based
tests. In most cases, there is simply not enough material to test for
every gene mutation that is available, and therefore a more effi-
cient use of the patient’s specimen is needed. For these reasons,
it is clear the “one-drug/one-gene Dx” paradigm is unsustainable
and that the drive toward precision medicine is changing clinical
practice, and as it does, it will change the clinical testing paradigm
for cancer treatment decisions.
DISRUPTIVE SHIFT
Next-generation sequencing is a classic disruptive technology (23).
It may even change the way precision medicines are developed
(24). Although these changes will impact the healthcare commu-
nity and their patients, in this section we will only focus on the
potential impact on drug developers and manufacturers of Dx
tests. The crux of these changes is the shift from a “one-drug/one-
gene Dx” model to a “multi-gene Dx/many drugs” paradigm (25,
26). An oversimplification of the interaction between the drug
developer and the Dx company can be summarized as: the drug
company develops a promising drug and discovers late in devel-
opment that a Dx is needed to identify the appropriate patient
population. Then it works with the Dx company to develop the
test to detect and/or quantify the specific biomarker, and they are
both tested in pivotal trials. Thus, the drug drives the device devel-
opment. The use of a multi-gene or multi-transcript panel has
the potential to change that. Instead of a single drug developer
partnering to develop a single Dx test, what may happen is that
the device manufacturer may design an assay able to detect a myr-
iad of RNA or DNA biomarkers. That is, the device manufacturer
may drive content on the device and may proactively seek FDA-
clearance independent of a partnership with a drug maker. The
implication of this disruptive shift is a set of challenges that will
be discussed in a later section.
PRIMER ON NGS PLATFORMS
Several firms have developed small benchtop NGS sequencers for
the clinical Dxs market. The current leading platforms are the
MiSeq from Illumina, Inc. and the Personal Genome Machine
(PGM) from Life Technologies, Inc., which together comprise
>85% of market as of early 2014 (Bloomberg Businessweek,
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January 2014). The recent agreement between Roche Molecular
Diagnostics and Pacific Biosciences (PacBio) heralds the entry of
the latter into the Dx arena. Qiagen has announced that it will
release its benchtop GeneReader™ NGS platform in 2014. Key
factors that influence clinical labs’ adoption of a particular plat-
form include sequencing quality, turnaround time (TAT), cost per
sample, optimal ease of use for the operator, and sample multi-
plexing capability (recognizing that multiplexing is likely required
to reduce cost). We provide a brief overview of the main clinical
NGS technology platforms here and refer the reader to exhaus-
tive reviews on NGS technology and instrumentation advances
for further details on each (27–30).
ION TORRENT
Life Technologies’ Ion Torrent semiconductor sequencing technol-
ogy, which made its debut in 2011, is based on a sequencing-by-
synthesis approach in which individual templated DNA molecules
positioned in microwells on a semiconductor chip are sequentially
incubated with each of the four deoxynucleotide triphosphates
(dNTPs) to support DNA strand polymerization (31). Only the
dNTP complementary to the template is incorporated at the end
of each template strand. As each dNTP is incorporated, a pro-
ton is released, which acts as an indicator of base incorporation
and the number of bases incorporated consecutively. The result-
ing pH changes are recorded as voltage changes that convey the
sequence of bases for the flow. Advantages of this technology
include optics-free readout, low input DNA requirement (which is
critical for clinical practice), and longer read length with accurate
base calling (32).
ILLUMINA
The Illumina technology also utilizes a sequencing-by-synthesis
approach with bridge amplification (27). Clonally amplified DNA
templates are immobilized to an acrylamide coating on the sur-
face of a glass flowcell that serves as the reaction and sequencing
substrate. Fluorescently labeled reversible-terminator dideoxynu-
cleotide triphosphates (ddNTPs) are added one base at time in
this sequencing technology. After the addition of each nucleotide,
the clusters in the flowcell are imaged to determine which fluores-
cent dye was incorporated. In its current manifestation, Illumina’s
greatest strength is the easier workflow of the amplicon library
preparation and reduced hands-on time as compared to other plat-
forms. Data from research versions of the technology, such as the
larger HiSeq platform, associates Illumina with greater accuracy
of base calls and lower indel detection errors (29).
PACIFIC BIOSCIENCES
To compete in the clinical and Dx space, PacBio introduced the
desktop RS machine in 2011. PacBio utilizes single molecule real
time (SMRT) sequencing. DNA template bound to DNA poly-
merase molecules is attached to the bottom of 50 nm-width wells
termed zero-mode waveguides (ZMWs). Each polymerase mole-
cule carries out second strand DNA synthesis using γ-phosphate
fluorescently labeled nucleotides present in the reaction mix. The
ZMW width does not allow light to propagate, but energy pene-
tration excites the nucleotide fluorophores in the vicinity of the
polymerase at the bottom of the well. As DNA synthesis occurs,
the incorporation of each base creates a distinctive pulse of flu-
orescence, which is detected and recorded in real time (33). In
a platform comparison of the three technologies, Quail et al.
noted the high fidelity of PacBio data and the ability to read long
sequences (28), but added the caveat that very high read depth
is required for achieving accuracy near that of MiSeq and PGM.
Additionally, in the context of formalin fixed paraffin embedded
(FFPE) and fragmented DNA material, PacBio’s long read strength
may not be of great advantage.
It must be noted that the rapid pace of performance improve-
ment of both the Illumina and Life Technologies benchtop
sequencers has been instrumental in making NGS-based Dxs
within reach (34). Both platforms have incrementally increased the
quantity and quality of base calling while reducing library prepa-
ration time and allowing on-instrument primary and secondary
data analysis, which was considered the largest bottleneck to clini-
cal and Dx NGS up to early 2011. For example, advances in library
preparation have reduced processing times two-fold compared to
older version kits available from both companies in 2011. On the
instrumentation side, the new, smaller instruments (MiSeq and
PGM), have enhanced output and accuracy of base calling com-
pared to the earlier larger throughput NGS instruments (Illumina
GAIIx, Illumina HiSeq 2000, and earlier versions of PGM) (28).
An Ion Torrent 318 chip with 400 bp sequencing reads can easily
produce >1 Gbp aligned data passing Q20 scores. Furthermore,
the newer versions of chemistry have significantly improved the
average error rates over the length of reads. Also, the design of
the new emulsion PCR (ePCR) Ion One Touch 2 system released
in late 2012 increased the uniformity of sequencing by enhanc-
ing inclusion of low length template Ion Sphere particles (ISPs)
in the template and enhancing library templating for sequencing.
Additionally, on-instrument analysis improvements significantly
reduced the challenges and time constraints imposed by bioinfor-
matic analysis. Although even more improvements are anticipated,
these technical advances have made clinical NGS a reality.
OPERATIONAL CHALLENGES FOR NGS ASSAYS IN THE
CLINIC
SPECIMEN TYPE AND AMOUNT
One of the key considerations with current clinical NGS tests with
Dx aspirations is the reliance on FFPE material. DNA isolated
from FFPE specimens presents unique challenges in being highly
degraded and of poor quality compared to that from fresh frozen
specimens (35). This places a limitation on the size of amplicons
that can be reliably amplified from this material, with tests tar-
geting amplicon targeted regions from around 120–180 bp (Ion
Torrent AmpliSeq Cancer Hot Spot panel)1 to ~175 bp (Illumina
TruSeq and TruSight assays)2. Additionally, DNA derived from
FFPE material undergoes cytosine deamination during the fixation
process, which can complicate analyses in downstream Dx applica-
tions unless a downstream bioinformatic solution is able to address
and compensate for such base alterations (36, 37). What is perhaps
an equally great challenge is the amount of specimen required for
the assay. Ion Torrent assays for cancer mutational hot spot panels
1www.iontorrent.com
2www.illumina.com
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require about 10 ng input of FFPE DNA, the Illumina TruSight
clinical assay panel requires 30–300 ng input DNA (as determined
by quantitative polymerase chain reaction (qPCR)-based func-
tional DNA assessment) and a majority of the established clinical
NGS panels available as lab-developed tests require about 40µm
FFPE material or >100 ng input DNA, in addition to sections
for pathology review and tumor markup. In contrast, individ-
ual Dx tests using either traditional Sanger sequencing or other
PCR-based assays typically require at least 15µm input per assay.
This apparent drawback of large input NGS-based testing (partic-
ularly for Illumina assays) has led to methods to reduce sample
requirements, such as Rubicon Genomics ThruPLEX kit, Illu-
mina’s Epistem technology, NuGen amplification products, and
New England Biolabs NEBNext Ultra for low input NGS. Impor-
tantly, the assay manufacturers have themselves adopted steps to
further decrease input amount for assays without compromising
on test sensitivity. One final note: for NGS-based tests, the sample
requirement for material is relatively independent of the number
of genes in the assay since the test requires the input of a minimal
number of amplifiable genomes only (38).
ASSAY TURN-AROUND TIME
A major hurdle in the adoption of a NGS-based test as a CTA is
the logistics in terms of the length of time from sample collection
to reporting of results. Most clinically applicable NGS-based tests
require 7–14 business days TAT (39). In the case of hematologi-
cal malignancies, such a long reporting time seems to be clinically
untenable. Some clinicians are hesitant to use NGS tests for patient
stratification and prospective enrollment in trials because patients
may not be willing or able to wait 2 weeks for a test result, and
thus will pursue other clinical trials in the meantime. As the
NGS assay TAT continues to improve (discussed under analyti-
cal challenges) this is likely to be a smaller concern in the next few
years.
AVAILABILITY OF CROs WITH CLIA NGS CAPABILITIES
Clinical trial sponsors typically prefer to perform clinical trial sam-
ple analysis in a single central lab to avoid potential liabilities of
using multiple local hospital laboratories, which can compromise
results or complicate interpretation due to the use of different
tests, different instruments, different validation standards, and
quality control (QC) processes, and different histopathological
practices such as macrodissection (14, 40). Unfortunately, despite
the potential commercial opportunity that available NGS-based
multi-gene panels represent, only a few contract research organi-
zations (CROs) or specialty testing labs have invested the effort
to develop the expertise to offer NGS services as Clinical Lab
Improvement Amendment (CLIA) laboratory tests suitable as
CTAs. Thus, the majority of the technical expertise does not reside
in traditional central labs and CROs (11), but rather in academic
institutions and in large clinical hospitals, where medical practi-
tioners have begun to use NGS-based mutational profiling screen-
ing to match their patients to the appropriate therapeutic (41).
These factors represent a significant challenge for pharmaceutical
companies interested in developing NGS-based CDxs.
The concern about using local laboratory for enrollment to
clinical trials comes from several different areas. First, there may be
variability due to different interpretation of the various guidelines,
checklists, and recommendations available for NGS assays (42–44)
since laboratory directors have some discretion and may interpret
the rules differently in some cases. An example is the interpretation
of the College of American Pathologists (CAP) NGS checklist that
recommends orthogonal analytical confirmation of all encoun-
tered mutations from an assay before the mutation is reported as
clinically actionable (43). This guidance seems to be interpreted
differently in different labs based on the availability of subjects,
which limits the probability of encountering samples with said
mutations. Second, the current lack of standardization between
hospital laboratories, especially in analytical and post-analytical
processes, introduces risk in, for example, mutation calls for the
same samples since they may utilize different platforms, assays,
software, and algorithms to make mutation calls. This is even seen
for simpler, non-NGS-based assays such as for KRAS mutation
detection assays. In a retrospective study (29) in which specimens
from colorectal cancer patients treated with panitumumab (an
anti-epidermal growth factor receptor gene (EGFR) monoclonal
antibody) were analyzed for the presence of activating KRAS muta-
tions in both local hospital labs and a centralized testing facility
at a CRO, the authors found that 6 of the 60 patients tested had
mutations and should have been excluded from the study. The
conclusion was that the LDTs in local hospital labs failed to detect
the KRAS mutations, allowing ineligible patients to be enrolled,
and thereby diluted the drug response rate since patients with
KRAS mutations were not expected to respond to panitumumab
treatment (45). That this can happen with a simple PCR-based
mutation test illustrates the risk associated with complex assays
such as NGS-based assays (43).
The challenge for the pharmaceutical company is how to run a
clinical trial that maintains the homogeneity of the trial popula-
tion in light of the paucity of CROs with CLIA NGS capabilities.
Some have suggested to use the local lab test as a CTA for enroll-
ment but confirm the result with a centralized assay or to use
the local lab test as a screen to identify patients whose samples
should be analyzed by the centralized CTA. Both of these sug-
gestions are problematic. First, analyzing the patient specimen by
two assays unnecessarily consumes limiting material. Second, dis-
cordant calls are inevitable, especially for assays as complex as
NGS-based assays. Determining which of two discordant results
is accurate will likely be time-consuming and expensive. Fur-
thermore, the discordant data will likely raise concerns of any
regulatory agency reviewing the clinical trial and it may call into
question the accuracy of the CTA. Similarly, the idea to use local
lab assays to screen patients for subsequent central lab testing will
definitely introduce a patient population bias if the study only
enrolls biomarker positive patients (12), and it may introduce a
bias even if the study has both biomarker positive and negative
arms. In general, it seems better to focus on reducing the TAT of
sample analysis at the centralized laboratory than to rely on local
laboratories for patient eligibility decisions.
A new paradigm in clinical NGS testing is the emergence of
companies like Foundation Medicine (FM) and Personal Genome
Diagnostics (PGD), which offer NGS-based panel tests as CTAs
to support clinical trials as well as directly to physicians. Boston-
based FM offers the Foundation One panel that reports on the
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mutational status of 285 genes that are found to be commonly
mutated in cancers; it has also recently announced a similar panel
for hematological malignancies (46). PGD, based out of Balti-
more, offers a clinical targeted cancer gene panel cancer select
for the detection of genetic alterations in 120 well-characterized
cancer and pharmacogenomics genes (47). These companies thus
offer an alternative to local laboratory testing for clinical tri-
als. Companies can either use one of these commercial panels
as a CTA or can establish a clinical trial protocol that enables
recruitment of subjects that have already had the tests performed
(13, 48, 49).
FDA-CLEARED INSTRUMENTATION
Although Illumina’s MiSeqDx instrument received CE marking in
June 2013, the lack of commercially available instrumentation was
a major hurdle to CDx development prior to the FDA-clearance
of Illumina’s MiSeqDx platform as a class II device in Novem-
ber 2013 [510(k) number K123989]. In addition, the FDA also
made the device and substantially similar devices exempt from the
premarket notification requirements. At the same time, the FDA-
cleared Illumina’s cystic fibrosis carrier screening assay, an assay
that detects all 139 variants in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene, as well as an assay for CF
diagnosis by sequencing all the medically relevant regions of the
CFTR gene assay (Source accessdata.fda.gov and illumina.com).
The type of data required for these submissions provides the first
documented and public view into the Center for Devices and Radi-
ological Health’s (CDRH) specific expectations for verification and
validation of NGS-based Dx tests; see below for a section in which
this is discussed in detail.
Life Technologies’ has recently stated that its Ion Torrent PGM
Dx System will be registered as a class II 510(k)-exempt device with
the FDA, as opposed to applying for 510(k) clearance as was done
for the Illumina MiSeqDx (50). This is apparently prompted by
the FDA decision that the MiSeqDx instrument and substantially
equivalent devices of that generic type will be classified into class II
and be exempt from premarket notification requirements [510(k)
K123989]. The Ion Torrent PGM Dx will be building on Life Tech-
nologies’ expertise with Dx instruments such as the 510(k)-cleared
3500 Dx Genetic Analyzer. The PGM Dx instrument will be an
open platform for NGS tests but without specific assays submitted
to the FDA. Life Technologies has stated that Dxs manufacturers
applying for tests on the PGM Dx will reference the master file as
needed to support their submission to the FDA and those assays
would be evaluated by the FDA through either the 510(k) or pre-
market approval (PMA) processes. The Ion Torrent system has
one significant difference in that it includes two peripheral acces-
sory instruments, the Ion OneTouch Dx for ePCR-based template
preparation and the OneTouch ES Dx for magnetic bead-based
ePCR library enrichment.
Pacific Biosciences RS II DNA Sequencing System’s regula-
tory path is currently not clear. However, in a significant move
recently, Roche Diagnostics and PacBio entered into an agree-
ment to develop Dx sequencing systems and consumables uti-
lizing PacBio’s SMRT technology. Per this agreement Roche will
become the exclusive worldwide distributor for PacBio’s human
IVD products (51).
TECHNICAL AND ANALYTICAL CHALLENGES FOR NGS
ASSAYS IN THE CLINIC
DESIGN OF THE NGS ASSAY
The first challenge toward a successful NGS CDx is the assay
design. Most current clinical NGS assays rely on a hybrid-capture
or PCR amplicon-based approach to provide overlapping, high
density coverage across regions of interest (52). When working
with FFPE biopsy specimens, the number of amplicons needs to be
judiciously optimized to allow efficient coverage of large regions
while keeping amplicon size small to enable efficient amplifica-
tion of formalin-damaged DNA (53). The choice of platform
and the degree to which the assay needs to include promoter,
3′ untranslated region (UTR), splice sites, or introns also affects
assay design. Currently, most commercially available panels only
cover exonic regions. While Ion Torrent’s hot spot mutation pan-
els cover shorter fragment amplicons, Illumina’s exon coverage-
based design tends to favor longer amplicons. While overlapping
longer amplicons may increase the fidelity of readout by utiliz-
ing multiple overlapping fragments per base, amplicon length
must be judiciously balanced to enable FFPE fragmented DNA
analysis.
Genomic complexity of the region of interest can impact accu-
racy and precision of an assay (54), so it is also important to
understand and to give due consideration to the same in assay
design. Since the genome has been shown to replicate at differ-
ent times with variable error as a function of time of replication,
the analytical parameters including error rate must be calculated
accordingly for specific regions based on sequence context (55, 56).
Knowing whether the region of interest is a region of lower intrin-
sic fidelity allows one to improve accuracy by compensating with
higher read depth. Similarly, the degree to which samples will
be multiplexed must be planned into the design to balance read
depth (and thus higher confidence in calls) versus the cost of the
assay, since higher read depth leads to lower multiplexing capacity
and thus increased per sample assay cost (43, 57, 58). Ensuring
that the assay design and bioinformatics analysis take into account
the region’s characteristics, it should be applicable to individual
assay developers building Dx assays on other platforms as well.
Finally, it is important to develop models that take into account
the expected sample throughput, frequency of testing, the assay
TAT, and the degree of batching to forecast the optimal multiplex-
ing strategy. For batching samples there must exist guidelines for
standard multiplexing and read depth to ensure equivalence of test
results.
QUALITY CONTROL STANDARDIZATION
The lack of industry-wide standardization of critical compo-
nents of QC also represents a challenge for CDx development.
The current NGS technologies have higher error rates and novel
error modes compared to traditional sequencing, which results in
variability in mutation reporting (59–61). Thus, during test devel-
opment it is essential to have a strategy to detect and reduce the
frequency of false positives and then to establish QC procedures
to assess test performance, yet there is no established or generally
accepted approach (62, 63). This strategy will likely involve vary-
ing bioinformatics parameters of the variant calling software and
establishing a method to confirm mutation calls with orthogonal
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methods. Investigating false positive calls is crucial during assay
development and refinement. While Sanger sequencing is still
considered the gold standard, its lower sensitivity of detection
[around 17–25%; (64)] limits its use for confirming mutations at
the low frequencies that are commonly detected with NGS. Multi-
ple strategies for orthogonal validation are possible, such as using a
different assay design on the same NGS platform to evaluate design
robustness or employing an orthogonal NGS platform with similar
sensitivity to identify any platform-specific artifacts. Orthogonal
validation with non-NGS platforms such as Sequenom, COLD-
PCR, and pyrosequencing may be a preferable approach and these
are also gaining popularity as clinical NGS validation strategies
(44, 46, 65). False negative calls are more difficult to detect but
the utilization of variant call files (VCFs) that report read depth at
every position allows for positive confirmation of a wildtype call
and not just the absence of a variant call at that position. Second,
standardized procedures for QC, including spike-in sequences are
yet to be standardized. Some have proposed that spike-in sam-
ples should mimic the region of interest in terms of genomic
region tertiary structure, interfering genomic regions compet-
ing for similar priming sites and, lastly, for genomic complexity,
including but not limited to base distribution, presence of simi-
larly presented homopolymeric regions or the known regions of
ambiguity such as GC combinations that have been found to com-
plicate variant analysis in a platform-specific manner (29). Recent
forums for NGS standardization (43, 44) have discussed the needs
for both artificial sequences, which will allow quality assessment
of library preparation and analysis (66), and clinically relevant
biological mimics, which can faithfully recapitulate biological vari-
ation induced by genome complexity as well as serve as a good
benchmark for matrix-associated artifacts, e.g., FFPE matrix arti-
facts. Without industry-wide recommendations or guidance from
regulatory authorities, this aspect of CDx development represents
a challenge.
CLINICAL AND DIAGNOSTIC RNASeq ASSAY DESIGN CHALLENGES
The use of RNASeq for transcriptional profiling, gene expression
studies, identification of variants, and pathological fusion or splic-
ing events (67) is an area of great interest to the clinical genomics
community. Clinical RNASeq brings to the fore the capacity to
utilize gene expression signatures for highly informative disease
sub-type classification or prognosis signature development, as has
been demonstrated by gene expression based Dx tests like Agen-
dia’s MammaPrint test (68) or Genomic Health’s OncotypeDX
tests (69). Clinical RNASeq at the whole transcriptome level offers
invaluable insight into a patient’s transcriptome and associated
gene expression changes informative of pre-disposition to cancer
or patient stratification strategies. It is especially pertinent for con-
ditions where alternative splicing and isoform selection can affect
response to drugs or can predict selective outcomes in response
to therapy. RNASeq analysis can be used to develop a robust mol-
ecular sub-type signature for a cancer as is apparent from recent
studies utilizing gene expression signatures for prognostic and Dx
assays (70, 71). In reality, as with issues facing the whole genome
sequencing and whole exome sequencing field, it is more likely that
targeted panels rather than whole transcriptome offerings will first
show clinical utility.
Some of the issues that hinder the adoption of clinical RNASeq
are the quality of the RNA from clinical biopsy materials, extremely
complex bioinformatics and statistical analysis as well as design of
the experiment and its execution in the clinic. The quality and
quantification of RNA is critical for successful library prepara-
tion and QC controlled analysis of the sample. Clinical FFPE
sample-derived RNA is likely to require pre-processing repairs or
methodologies to enable low input amplification or enrichment
based library preparation. Sample RNA preparation and RNASeq
process reproducibility and accurate quantification will have to
be highly validated to avoid issues such as prep based biases in
quantification of GC-rich transcripts or small RNA species. It will
also be important to assess the impact of factors such as RNA
secondary structure, the presence of small RNAs in the sample or
interfering substances (72). Any lack of read-out reproducibility
in a gene-specific manner will hinder the establishment of fold
change cut-offs for clinical decision-making (73). Qualifying ade-
quate depth of coverage is critical because accurate quantification
of transcripts in clinical RNAseq is dependent on read depth (74).
The bioinformatics analysis of RNASeq in the clinic is consid-
erably more complex than pipelines for DNASeq. For one thing,
normalization of data needs to be highly accurate for the technol-
ogy to be quantitative for the measurement of relative expression
values (75). As algorithms for non-clinical RNASeq are improved
and as scientists employ better controlled experiments and statis-
tical strategies (76), some of the issues that have plagued clinical
RNASeq bioinformatics may be resolved in the near future. Def-
inition and standardization of clinical databases and annotation
pipelines is another critical requirement for clinical RNASeq. Cur-
rently, because of variability in gene models in different databases
such as AceView and RefSeq as well as frequent changes to the
databases, non-clinical RNASeq efforts encounter high variability
in definition and annotation of regions. In addition, one of the key
features of clinical RNASeq will be the ability to identify specific
re-arrangements and spliced isoforms. Considering that detection
of fusions and gene re-arrangements have high clinical relevance,
it will be necessary to develop both bioinformatics methods and
mate pair library construction protocols or similar technology but
simpler workflows to detect re-arrangements and gene fusions
(77). The design of targeted experiments should enable more
hypothesis-free quantification of the staggering complexity of
gene fusions and transcript re-arrangements possible as well (78).
Without such a highly complex identification and quantification
strategy the power of clinical RNASeq cannot be fully realized.
Targeted RNASeq approaches, particularly with amplicon-based
panels, would need to have highly plexed designs to allow a more
discovery oriented capture approach while allowing highly sensi-
tive quantification. Hybrid capture based panels would possibly
offer more robust splice isoform coverage but suffer from more
labor intensive protocols.
Reference materials, controls, and QC standards need to be
defined for clinical grade RNASeq in the same way these are
becoming standardized for clinical DNASeq. An advantage for
the clinical RNASeq field is the availability of the highly quali-
fied human reference MAQC-A and MAQC-B reference materials
and the extensive data on tissue-specific expression of potential
housekeeping genes from exhaustive microarray profiling (79).
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This approach has been utilized to test and aid data correction
in RNASeq in research settings and may find easy integration
into clinical practice as well (80). Recently, the set of eukaryotic
mRNA mimic Spike-In Control Mixes developed by the External
RNA Control Consortium (ERCC) has been suggested as a clini-
cally useful control option. These have pre-formulated quantified
blends of 92 transcripts derived from National Institute of Stan-
dards and Technology (NIST)-certified DNA plasmids. The call
for a MAQC-like platform comparison for RNASeq to identify
issues and to evaluate platform-specific biases or strengths is being
addressed by at least two consortia, the FDA’s SEQC (MAQC-III)
group and the Association of Biomolecular Resource Facilities –
Next-Generation Sequencing (ABRF–NGS) group study. These
results will be highly informative to the developers of clinical RNA
sequencing (RNA-Seq) assays.
An emerging theme in the translational NGS community has
been the utilization of RNASeq for detection of mutations (81,
82). Analysis pipelines that can account for factors like editing
biases are not publicly available or are not sufficiently validated to
allow such analysis in a clinical context, but once achieved these
may offer a highly efficient method for capturing both mutational
and expression level information in the same analysis (24, 83).
Increasingly, studies that compare the benefits of both types of
studies in combination with even epigenetic and microRNA sig-
natures of the tumor for comprehensive profiling are likely to
gain traction. The use of RNAseq instead of clinical DNASeq is
likely to require a significant effort that includes matched RNAseq–
DNAseq analysis and the development of sophisticated algorithms
for analysis. Nonetheless, it appears likely that for at least certain
molecular sub-types RNASeq-based gene expression profiling and
analysis may provide a more predictive result than mutation based
analysis alone.
POST-ANALYTICAL CHALLENGES
BIOINFORMATIC MUTATION CALLING ALGORITHMS
One of the major hurdles to adoption of NGS for CDxs is the
current state of variability in the performance of variant call-
ing software depending upon the bioinformatics pipeline used
(84, 85). It is a routine occurrence that variations in mutation
detection are observed from the same raw data set when utilizing
different algorithms for variant calling, even with the assumption
that similar pre-variant calling processing was performed on the
final dataset (86). Figure 1 is a high level schematic illustrating
the basic steps in a bioinformatics pipeline to stress the number
of steps and the complexity of variables that impact mutation
detection. The initial sequencing data (DAT files) are derived from
Illumina imaging data or Ion Torrent pH change related voltage
data. Basecall (BCL) files contain data where the sequencing data
(images or voltage) have been translated into a nucleotide call.
Multiplexed data are then separated into per sample data via the
sequencing index identity and FASTQ files are generated, which
contain sequencing read data that include the sequence and an
associated per base quality score, called a phred score or Q score
(87,88). Reads are then aligned to a known reference sequence con-
taining genomic coordinates and organized into BAM files (89).
Variation analysis, or variant calling, refers to the assignment of
FIGURE 1 | Schematic representation of the various
bioinformatics and statistical analysis steps of a typical clinical
NGS variant detection data pipeline. The graphic illustrates the
major modules of the pipeline and their output file types, beginning
with raw reads (DAT files) and ending with a clinical report. The
pipeline is highly tunable, as each of the steps can be optimized by
adjusting parameters specific to each step. The triangular shape is
intended to convey that each step acts as a filter to remove reads that
do not represent variants. The key quality filters that can be applied
are shown in the boxes to the right.
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non-reference status (i.e., a mutation or a variant) to a specific
queried position in the genome and generates a tab separated VCF.
The variant calls are filtered to minimize false positives and false
negatives while maintaining the sensitivity and specificity of the
data by utilizing the phred quality scores, which vary on different
platforms (63). To generate a clinically actionable report, the high
confidence variants are unambiguously annotated based on clin-
ical data showing a causal relationship between the variant and
disease and with information about the variant in the literature
(90, 91). A vast variety of software is available for each step of NGS
data analysis, as are a number of bioinformatics suites designed
specifically for Dx testing and which can be tailored to provide a
streamlined, module locked analysis for Dx processing (63, 91).
Some suites may also allow the user to change settings for test
development purposes. Recently, the NIST spearheaded an effort
(92) to develop a highly confident variant caller by encouraging
the NGS community to share sequencing data of their NGS ref-
erence material NA12878 (v.2.15). This effort should greatly aid
the standardization of analysis methodology and better QC for
assessing false positives and false negatives (66, 92).
The traditional regulatory framework makes integration of the
NGS data analysis software into the Dx device system imperative,
with a fixed version of the analysis algorithm for the regulatory
submission. This presents a challenge for the device developers
since variant calling software applications are continually evolv-
ing, particularly in the ability to detect indels, in efforts to reduce
analysis time and in the use of control set parallel analysis (41, 85,
86, 93). As new versions of variant calling software with better sen-
sitivity and specificity become available, it is reasonable to assume,
based on current precedent, that new 510(k) submissions will be
required for these devices.
Standardization of data QC and filtering, variant detection
and annotation of samples is imperative for developing Dx tests.
Ideally, NGS-based data analysis should be subjected to rigorous
internal and external QC with rules to accept or reject data akin
to Westgard rules (94, 95) used for other analytical tests. The
field is still open for discussions on how these rules should be
implemented for NGS-based CTAs and Dx tests. For example, are
traditional Westgard rules applicable to a quantitative parameter
of NGS-based mutation detection tests such as mutation allele fre-
quency? If not, then what type of quantitative rules can be used to
establish in control processes? It is imperative for the field to define
the type of control samples and the QC procedures to accept or
reject runs. Some laboratories argue that internal control targets
must also be met prior to a decision to report mutations (43, 85).
Another novel aspect of NGS mutation calling is that variants
are rated based on the certainty of the call (87, 88). Phred quality
values are assigned to specific steps in the process such as base
calling and read alignment. Read depth, read quality, frequency of
detection of the allele, strand bias, annotation as germline variant
or variant of unknown significance, or lack of “actionability” all
can be used to assign a confidence score to a particular call (57, 89,
96). Segregation of variants per characteristics of read depth, base
quality, read quality, and strand bias are easily automatable with
most Dx instruments available, but current software programs
do not provide easy readout of mis-alignment-based read drops,
reads that are exempted from final analysis by homopolymer-based
inaccuracies, reference allele bias, or reference genome bias (60,
61, 97). These are post-analysis computing requirements that still
need to be built into software to minimize operator involvement.
It is interesting to note that each sequencing platform has its
particular advantages and drawbacks in terms of regional biases
that complicate variant calling. In the past, Illumina MiSeq data
have been associated with high accuracy but increased strand
bias with GC-rich motifs, as well as low accuracy for homopoly-
mer stretches beyond 20 bp (97, 98). In the November 2013 FDA
510(k) Decision Summary for the MiSeqDx instrument (Number
k123989), Illumina specifically claims the ability to detect sin-
gle nucleotide variants (SNVs) as well as deletions up to three
bases. Based on a very limited data set, the instrument can also
detect 1 bp insertions, but this is limited to non-homopolymer
regions, since the MiSeqDx instrument was shown to have prob-
lems detecting 1 bp indels in homopolymer tracts, e.g., polyAs.
The notification also states that Illumina’s current MiSeqDx analy-
sis software will automatically remove any homopolymer tracts of
longer than eight continuous identical bases (R8 error). Interest-
ingly, the MiSeqDx instrument claims to be a qualitative detection
platform rather than quantitative. The MiSeq has generally been
reported to have higher fidelity for indel calling than Ion Torrent
(28, 61, 99). Ion Torrent homopolymer regions beyond 20 bp tend
to be misaligned and discarded so that alignment algorithms must
be optimized per region of interest to allow inclusion of misaligned
regions (32, 61). The Ion Torrent Dx platform specifications will
become clear when it is registered. Strand bias related inaccura-
cies and decreased depth of coverage or uneven coverage (due to
allele dropout in case of sampling error or as a function of tumor
heterogeneity) can also compound the problem of mutation call-
ing inaccuracies. Accurate base calling algorithms for Dx assays
must minimally utilize spike-in controls during technical feasibil-
ity experiments and raw data controls for software training that
include mutation calls in regions of predicted poor base calling if
those are part of the assay design (41, 43, 66). The use of a highly
sequenced reference sample, such as NA12878 by NIST (v.2.15) for
software training and algorithm development has been proposed
in many forums such as the NIST “Genome in a Bottle” Consor-
tium (92). Recently, the same was used by Illumina to demonstrate
accuracy in its MiSeqDx platform 510(k) submission application.
Additionally, it is reasonable to propose to include engineered
mutations as part of spike-ins where inaccurate calls may result
due to biases from GC-rich motifs, strand bias, reference allele bias,
homopolymers, and regions of low coverage if down-sampling
total calls for normalization, etc. For assessing the accuracy of the
data pipeline, normal/reference sample pairs may be developed as
proficiency testing (PT) material. Alternatively, specially designed
artificial DNA mixtures that contain the majority of expected
mutations (from literature and clinical findings) should be used
as reference material in accuracy, sensitivity, and precision studies
in the technical feasibility phase. The National Cancer Institute
(NCI) initiative to make specific mutations available as plasmid
constructs as well as the availability of characterized mutant DNA
or recombinant tissues from companies like Horizon Dx are allow-
ing test developers to devise such experiments with spike-in-based
QC (43, 66). From its recent guidance on Personalized Medicine,
the FDA also seems to acknowledge that testing of variant calling
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FIGURE 2 | Aspects and key considerations of clinical NGS data
reporting. Main aspects of clinical data reporting are shown in ovals to the
left; key considerations are shown in boxes to the right. The uppermost three
aspects rely on the bioinformatic pipeline. What test results are reported in
the clinical report (fourth oval) is influenced by socio-ethical considerations
and may require genetic counseling and support systems. The evolving payer
landscape and medical records guidance will affect how NGS clinical reports
are captured in patient records.
for a specific set of mutations and the establishment of the plat-
form’s sensitivity and specificity may be sufficient for the clearance
of a NGS-based regulated device. One novel aspect to the applica-
tion of NGS-based tests is the need for a standardized set of raw
data for mutation calling algorithm development. To meet this PT
need, the NIST Genome in a Bottle Consortium as well as CAP
have both been actively advocating availability of public data sets
from extremely well studied samples as PT material to assess a par-
ticular pipeline’s sensitivity and specificity in mutation detection
to avoid lab to lab variation in mutation detection.
In addition to bioinformatics analysis for variant calling, there
are several aspects of data interpretation and annotation that must
be standardized for NGS tests to be adopted into clinical practice.
These are graphically represented in Figure 2 and are discussed
below.
DATA REPORTING
If the FDA requirement for a NGS-based Dx approval is demon-
stration of accuracy and precision for each assayed base, it is
possible that Dx developers may choose to limit the reportable
content of a NGS panel by utilizing base masking in an effort
to reduce the extent of analytical validation efforts. In the recent
510(k) application for the MiSeqDx instrument and the CFTR
gene Dx test on the instrument, data showing the orthogonal
validation of a subset of base positions was accepted, suggesting
that the FDA may only require a sponsor to show performance
data for the unmasked, reportable nucleotide positions on future
submissions of panels or single-gene assays. It will be interesting
to note the Agency’s guidance on this topic since the masked data
could potentially still be utilized for analysis to develop or enhance
predictive mutation signatures on retrospective analysis.
Another key consideration for data reporting is the report-
ing of variants of unknown significance. The ACMG guidelines
from 2008 (100) defined various cases of variants of unknown
significance including: (1) previously unreported variations with
possible ramifications for the disease being studied. This includes
indels, frameshift mutations, and invariant splice site AG/GT
nucleotides variants that can alter the reading frame and thus the
expressed gene product. (2) Previously unreported variations that
may or may not be causative of the condition. These are exem-
plified by missense changes, in-frame indels, and splice consensus
sequence variants or cryptic splice sites that may affect regulatory
processes, e.g., interruption of splicing enhancers or suppressor
sites. In these cases, clarification of the clinical significance of vari-
ants is required and it may be important to flag them accordingly
in a report. (3) Previously unreported variations that are prob-
ably not causative of disease, e.g., synonymous mutations that
do not alter protein sequence or affect processing or regulatory
pathways, or are found in addition to a variant known to be asso-
ciated with pathologic change (in autosomal dominant disorders).
(4) Previously reported sequence variations that are recognized
as neutral variants with evidence available that the variation has
been consistently observed in a normal population and does not
associate with disease or predisposition to disease. (5) Sequence
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variation not known or expected to be causative of disease, but
is found associated with a clinical presentation, e.g., variants that
contribute to disease as low-penetrance mutations which alone
or in combination may or may not predispose an individual to
disease or modify the severity of a clinical presentation in com-
plex disorders. For such a category the institute suggests reporting
as not definitive mutations and stating that medical management
decisions should not be made on the presence of the variants
alone. This last is probably the most efficacious solution for report-
ing NGS-based variants of unknown significance since it allows
capturing of the profile without unduly triggering medical action-
ability. Unfortunately, the current forms of patient consent are
usually quite limiting and restrict public sharing and analysis of
data utilizing big data analytics. There is clearly a need for patient
consent agreements to allow meta-analysis, but this is the topic of
the next section, data privacy in the age of big data analytics.
Reporting of incidental or serendipitous findings is another
area of complexity for NGS-based tests. Some are proponents of
the idea that incidental findings should not be reported at all in
clinical sequencing without strong evidence of benefit, while oth-
ers advocate that any and all variations in disease-associated genes
are potentially medically useful and therefore should be reported
(2, 17, 41, 44, 46). Recognizing the difficulties of reporting such
secondary findings which are medically important but unrelated
to the reason for test ordering, the ACMG constituted a special
Working Group on Incidental Findings in Clinical Exome and
Genome Sequencing to make recommendations for addressing
such findings in pretest patient discussions, clinical testing, and
the reporting of results (101). In the case of targeted oncology
panels, this may not be an issue unless specific loci are associ-
ated with enhanced risk for other conditions or where particular
polymorphisms can affect existing health care routines and drug
regimens. Currently, the ACMG working group has only recom-
mended reporting those incidental findings for which preventive
measures or treatments are already available or for disorders in
which patients are asymptomatic despite the presence of patho-
genic mutations. Generally, the recommendation was to report
pathogenic variants as incidental findings, e.g., those where the
“sequence variation is previously reported and is a recognized
cause of the disorder” or “sequence variation is previously unre-
ported and is of the type, which is expected to cause the disorder”
(100). These two were chosen no doubt because the group recog-
nized that attempting to report and interpret variants of unknown
significance as incidental findings would be particularly challeng-
ing. The report also stressed that identification of monogenic
diseases via a clinical NGS panel as an incidental finding is highly
improbable by current practice.
PRIVACY OF AND ACCESS TO PATIENT RESULTS
Ever since the report that individuals could be identified from
anonymous NGS data (102), privacy groups have been justified
in their concerns about having sensitive data made public as a
result of inappropriately controlled data and reports. Privacy of
patient results is also linked to maintaining the highest standards
for patient consent to NGS-based testing, anonymized data gener-
ation, secure data storage, encryption, and transfer processes that
meet the highest standards data (103). The converse of this concern
relates to the data that reported back to the patient, especially
incidental findings unrelated to reason for which the test was per-
formed. In contrast to whole genome sequencing, oncology-based
panels are focused on tumor specific genes assessed in the context
of the tumor. They have less content with associated incidental
findings and thus are less likely to trigger traditional socio-ethical
impact (104). However, an issue which lacks resolution is the
reporting of low frequency mutations for which the allele fre-
quency based drug action has not been studied. For example, the
technical sensitivity of an assay may allow the detection of a mutant
at 0.1%, but there is no framework with which to interpret such
a finding, and reporting it to the patient may cause more harm
than good.
INTERPRETATION OF RESULTS
The mainstream adoption of NGS Dxs will rely heavily on easily
interpretable test results. One critical aspect of data interpretation
with NGS-based tests is the comparative reference human genome.
This is an individual genome and may not be an ideal reference
genome for most individuals in the population. For this reason,
some commercial NGS providers have started stressing the need
for a matched germline control comparator sample such as periph-
eral blood or normal adjacent tumor tissue from tested individuals.
The constant evolution and enhanced annotation of the refer-
ence genome as sequencing-based studies continue to reveal new
genomic complexities also confounds interpretation. In the exam-
ple from the MiSeqDx 510(k) decision summary, it is interesting
to note that a compound reference genome derived from two well-
characterized samples was utilized in addition to human genome
build 19 [NCBI Human reference February, 2009 (GRCh37/hg19)
assembly] [FDA 510(k) K123989 decision summary]. For exam-
ple, the two genomes differed in a particular homopolymer run,
which was a run of 14 A’s according human genome 19, while the
sequence in the composite reference genome had a run of 15 A’s.
This was significant because it directly impacted interpretation
of the MiSeqDx sequencing accuracy study, since all 13 samples
analyzed were reported as having 1 bp insertions since 15 A’s were
detected in all 13 samples. As new variants and polymorphisms
are identified, it may be warranted to re-annotated or re-issued
reports to include the new data or its new interpretation.
OVERVIEW OF DIAGNOSTIC TEST REGULATORY APPROVAL
PROCESS
As a prelude to the regulatory challenges, we digress to pro-
vide an overview of the Dx test regulatory approval process. The
basic regulatory pathway options for Dx device development are
summarized in Figure 3. This section describes a generic IVD sub-
mission process with the authors’ comments on possible paths for
NGS-based devices.
For any given test that is submitted for FDA consideration, the
route to commercialization may be via a 510(k)/pre-market noti-
fication process or via a PMA application. The decision to take a
NGS-based clinical test via the 510(k) or PMA process will depend
largely upon the perceived risk associated with the Dx device. The
510(k) Dx IVD process relies on the presence of a predicate device
or devices. However, FDA has utilized the de novo 510(k) path-
way when the risks of the new device are consistent with other
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FIGURE 3 | Regulatory models for development of NGS-based diagnostics. The FDA device classification for a regulated NGS-based diagnostic device will
depend on the perceived risk associated with the diagnostic device.
510(k)-cleared devices but a clear predicate is not available. The
510(k) process may be appropriate for those NGS-based tests that
will be utilized for monitoring disease or for tests where the per-
ceived risks are lower. Although the concept of a predicate device
is woven into FDA’s device regulation, the reality for the genetic
tests that have been cleared or approved to date is the new system
is not compared head-to-head with a previously cleared system.
Rather, the new method is compared to a gold standard method,
which is considered truth. For most DNA applications, the gold
standard has been bi-directional Sanger sequencing. Applications
which have relatively higher perceived risk to the patient, such as
NGS-based oncology tests, will likely be required to go the PMA
route to demonstrate safety and efficacy. In these cases, a reference
method will also be used to demonstrate accuracy of the device.
A PMA submission for a CDx NGS test will entail coordinated
review of the drug by the Center for Drug Evaluation and Research
(CDER) and of the device by the CDRH (or CBER for certain dis-
ease indications). The IVD developer will have to demonstrate
the safety and effectiveness of the in vitro Dx device when used
as specified in the label. The Dx device must be considered as
an entire Dx system including reagents, hardware, software, data
analysis, and result reporting. Use of the device in the pharma-
ceutical clinical trial will provide important data to demonstrate
clinical validation of the assay. Although NGS IVD submitters may
have to undergo an advisory panel review regarding clinical, reg-
ulatory, scientific and statistical issues due to the novelty of the
NGS platform and assay structure and readout, it seems doubtful
since other CDx applications have not had this hurdle and FDA
has seen fit to clear the Illumina platform with no such advisory
panel requirement. For an approved PMA any modifications to
the test or device, manufacturing process, its labeling, intended
use or sensitivity or specificity would require FDA notification
and prior approval. In general, it is imperative that NGS-based Dx
stakeholders seek clarity utilizing pre-submission meetings with
the CDRH, and specifically the Office of In vitro Diagnostics and
Radiological Health (OIR), well in advance of trial planning. It is
important to engage in such discussions early as FDA thinking is
evolving rapidly.
Many of the regulatory challenges for CDxs are not unique to
NGS. Although NGS tests may be more complex than other tech-
nologies, the same principles will apply. The FDA’s expectations
on the analytical validation and performance characteristics of
NGS-based assays will differ somewhat for each individual assay.
However, the 510(k) clearance of Illumina MiSeqDx reveals some
aspects of the regulatory agency’s viewpoint on validation. Since
this is the crux of the regulatory challenge, we summarize in detail
the main aspects of Illumina’s 510(k) submission studies [510(k)
summary, e.g., K124006, November 2013] as early pointers to the
type of experiments FDA may expect.
510(k) CLEARANCE OF ILLUMINA MiSeqDx
With the MiSeqDx clearance, the FDA has given some indica-
tion the type of information that will be required for approval
a NGS-based CDx for tumor mutation status. First, the 510(k)
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summary indicates that accuracy data for all claimed speci-
men types and nucleic acid types were required. Two sources
of well-characterized samples (based on well validated sequenc-
ing methods) were queried with all of the claimed sequence
variation types, types of sequencing and with the sequences
located in varying sequence context (e.g., different chromosomes,
GC-rich regions). The 510(k) summary indicates that sequence
data generated with a sequencing technology platform and vari-
ant calling method independent of the device manufacturer is
required for at least one of the reference samples. Percent agree-
ment and percent disagreement with the reference sequences
were described for all the regions that were queried by the
instrument. Illumina performed accuracy testing in three stud-
ies. The first assessed overall accuracy over a wide portion of
the genome by utilizing 13 very well-characterized samples from
parent–child triads that had been sequenced by multiple labo-
ratories and multiple sequencing technologies. Human reference
genome 19 was used to assess accuracy across 24,434 bases on
19 chromosomes encompassing a variety of genes containing
potentially clinically relevant exons. The second study assessed
the accuracy of the MiSeqDx instrument at 17 highly confident
variant calls in the NIST NA12878 standard reference mater-
ial. The third accuracy study assessed the instrument’s perfor-
mance in detecting small insertions and deletions by analyzing
six samples using the Cystic Fibrosis 139 Variant Assay, which
included a subset of clinically significant indels in CFTR. The
detected insertions and deletions were all confirmed with bidirec-
tional Sanger sequencing as the reference method. Such accuracy
studies helped Illumina define its performance specifications for
homopolymer stretches, nucleotide repeat regions, and ability to
detect indels.
For precision/reproducibility studies, the 510(k) summary
indicates that data should be generated using on multiple instru-
ments, with multiple operators and at multiple sites, and that
performance data are required for all claimed specimen types,
nucleic acid types, sequence variation types, and types of sequenc-
ing. As discussed in the Assay Design, a special emphasis was
given to variants located in varying sequence context, such as
different chromosomes and GC-rich regions, along with a require-
ment to utilize a high confidence reference sequence data. To
this end, Illumina performed three precision studies. For the
first study, 13 well-characterized sequenced samples were ana-
lyzed in 9 runs using 3 different MiSeqDx instruments and 3
different operators. Samples NA12877 and NA12878 were run
in duplicate to assess repeatability. Ninety-four samples and two
non-template controls were tested across three lots to establish
lot-to-lot reproducibility of the Illumina universal reagents. Each
lot was split into two 48-sample runs to test reagents and all
possible index primer combinations. All sequencing runs were
completed by a single operator and on a single MiSeqDx instru-
ment to remove potential variance contribution from operator
or instrument. The MiSeqDx Cystic Fibrosis 139 Variant Assay
reproducibility study involved a blinded study with three trial
sites and two operators per site. Two well-characterized panels
of 46 samples each were used for testing. These contained a mix
of genomic DNA (gDNA) from cell lines with known variants
in the CFTR gene and variant containing cell lines spiked into
leukocyte-depleted blood to assess variability from the gDNA
extraction steps.
Illumina also addressed the issues of sample cross-
contamination (carryover) and intra-run performance. For intra-
run performance, a 48-sample library of two samples with unique
variants arrayed in a checkerboard of an alternating high concen-
tration (500 ng) and low concentration (100 ng) input was utilized.
For inter-run carryover 2 libraries were prepared each with 47
replicates of a single gDNA sample and 1 no template control
(NTC). The samples were unique in each library and continuous
run assessment was performed to demonstrate absence of carry-
over. The reproducibility and accuracy of multiplexing was also
tested with 12 indices (barcodes) per sample sequenced. Accuracy
for all sample/index primer combinations was confirmed as 100%
by Sanger bi-directional sequencing and PCR-based confirmation.
For testing the contribution of common interfering substances
to variability, four endogenous interfering substances (biliru-
bin, hemoglobin, cholesterol, and triglycerides) were spiked in
eight unique whole blood samples. Blood collection variability
and gDNA sample preparation variability were also evaluated,
along with sample input amounts, thermal cycler effects, and
sample stability. DNA extraction methods were assessed using
168 specimens (14 samples× 2 operators/extraction method× 3
runs/operator× 2 replicates/extracted gDNA sample).
The MiSeqDx approval gives insight into some of the regula-
tory expectations for NGS-based assays and is summarized here
with some general headers for reader clarity:
Specimen and processing-related validation:
(i) The specimen type(s) as source of nucleic acid.
(ii) The type(s) of nucleic acids (e.g., germline DNA, tumor
DNA).
(iii) The nucleic acid extraction method(s).
Sequencing variation-related validation:
(i) Type(s) of sequence variations (e.g., SNVs, insertions, and
deletions).
(ii) Type(s) of sequencing (e.g., targeted sequencing).
(iii) The read depth required for the sensitivity being claimed and
the validation data that supports those claims.
(iv) Accuracy and precision of the test and the types of sequence
variations that the test cannot detect with the claimed accu-
racy and precision (e.g., insertions or deletions larger than a
certain size, translocations)
(v) The upper and lower limit of input nucleic acid to achieve
the claimed accuracy and reproducibility.
The MiSeqDx instrument’s current de novo classification is for
qualitative assessment for profiling of peripheral whole blood sam-
ples, which tend to be of a higher quality. It is important to note
new tests, including CDx devices, on the platform are likely to
require PMA submissions, especially for tests utilizing heteroge-
neous samples like tumors. The current MiSeqDx clearance for
qualitative results opens the discussion on what further valida-
tion strategies may be required to achieve quantitative detection
of mutations (e.g., quantitative allele frequency), which may be
one of the strengths of clinical NGS.
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UNANSWERED ANSWERED REGULATORY QUESTIONS
HOWMANY MUTATIONS WILL HAVE TO BE CLINICALLY VALIDATED?
The FDA has hinted at possible accuracy requirements for com-
plex, multi-analyte specific assays, genes, and panels at the DIA
Meeting on Personalized Medicine and CDxs (November 6, 2013).
This provides important insight for CDx applications involving
tumor suppressor genes and certain oncogenes since actionable
mutations may occur anywhere along the length of the gene. FDA
has suggested three potential strategies:
• Sequence clinical samples from the intended use population and
compare to reference method results.
• Sequence procured samples that span the relevant classes of
variants and compare to reference method results.
• Sequence well-characterized reference sample(s) and compare
to reference sequence.
CAN AN NGS MULTI-GENE OR MULTI-TRANSCRIPT PANEL BE
APPROVED AS A DIAGNOSTIC PLATFORM, ALLOWING MULTIPLE CDx
SUBMISSIONS?
At the 2012 Friends of Cancer Meeting the FDA publicly indicated
their interest in reviewing NGS-based cancer panels similar to the
panels that have been cleared as microbiology devices (i.e., devices
that detect multiple viruses and bacteria in a single product) (105)
(focr.org). Although the details of this type of submission would
need to be worked out between FDA and an individual spon-
sor, it seems likely that some level of clinical evidence would be
needed for each gene or mutation included on the panel. It is pos-
sible, similar to the cystic fibrosis assays, that this list could be
developed based on medical input and literature. From that point,
more specific claims about individual genes could be made on a
gene-by-gene basis including CDx claims if the product has been
used as part of a clinical trial investigating a particular drug. It is
likely that any cancer panel would be subject to a PMA [rather than
a 510(k)], and amendments to the original PMA with additional
claims on a per panel member basis would be a rational approach
to updating the claims for each new CDx.
HOWWILL EXISTING GENOMIC DIAGNOSTICS ALIGN WITH APPROVED
NGS-BASED DIAGNOSTICS?
Currently, the intended use statement for each of the Dxs that
have been approved in conjunction with a drug list the drug name
in the intended use statement. It is reasonable to expect that this
policy will continue and that in order for a drug and Dx to be
co-marketed the drug and device will need to be linked. Even if
there are multiple devices available for testing in conjunction with
a specific drug, any of the approved devices will be allowed.
WHAT IS THE APPROPRIATE ORTHOGONAL TECHNOLOGY?
What is the true measure of truth when comparing discordant
results? FDA has shown with the recent Illumina clearance that
they expect NGS-based mutation calls to be confirmed by an
orthogonal technology (in many cases bi-directional sequencing).
However, disagreement exists within the NGS community as to
what is true orthogonal validation of a NGS-based mutation call
(17,64,106). The enhanced sensitivity of mutation detection down
to 1–5% allele frequency implies that orthogonal validation will
require a platform with similar sensitivity. While Sanger sequenc-
ing is being used to support mutation validation, for example in
the Illumina MiSeqDx 510(k) clearance, it is not possible to use
Sanger data to provide a definitive call when mutations in the
range of 1–15%. Generally, if NGS and Sanger give discordant
results labs tend to use tie breaker tests such as pyrosequenc-
ing or Sequenom-based sequencing on the MassArray system.
Both of these technologies can detect mutant allele frequencies
down to 5–10% frequency and are finding increasing usage in
NGS validation. As Sequenom and pyrosequencing vendors cre-
ate niche products tailored for NGS validation these will likely
integrate into clinical NGS workflows. The FDA has shown flex-
ibility in allowing use of these types of technology as orthogonal
methods when Sanger is not sensitive enough. However, the FDA
will insist on appropriate validation of these methods and will
expect to review these validation packages as part of the review
process.
Another approach, likely to be costlier but with the opportu-
nity to have near equivalent sensitivity of detection, is the uti-
lization of a second NGS technology for confirmation of assay
results, e.g., utilizing both the Illumina and Ion Torrent platforms
where the difference in underlying technology make a confir-
mation of positive results quite robust. The main issue to be
cognizant of is the need to adjust analysis parameters to provide
equivalent performance with respect to mutation call sensitivity,
since each platform uses its unique quality score for data quality
assessment. For example, while Ion Torrent recommends using a
phred value of Q20 (99% specificity) for high confidence vari-
ant analysis, Illumina recommends at phred value of Q30 (99.9%
specificity) for ensuring high confidence calls (61). The difference
in acceptable phred scale values arises from differences in plat-
form technology, related background signal and noise calculation
algorithms (107).
STRATEGIC CHALLENGES FOR DRUG AND DIAGNOSTIC
DEVELOPERS
Developing any CDx can be enormously challenging, as seen in the
development of the BRAF mutation (108) and ALK gene fusion
(109, 110) tests. A primary reason is that the device development
timeline does not align with the drug development timeline, as
illustrated in a development timeline chart (Figure 4) (15, 108,
111). Ideally, CDx development for the NGS assay would start with
the initiation of early phase studies (Ph1/2a studies in Figure 4)
to allow sufficient time for development of the Investigational Use
Only (IUO) version of the device before start of the phase 3 piv-
otal trials. But this is not often the case, and compromises and
work-around strategies are sometimes necessary. Thus, in another
example of navigating the rapids, pharmaceutical and Dx compa-
nies face some unique challenges in NGS-based CDx development,
which are summarized in the next sections.
DRUG DEVELOPMENT CHALLENGE 1 – IS A COMPANION DIAGNOSTIC
NEEDED?
The first challenge is whether a co-Dx test is in fact required and
how a multiplexed RNA- or DNA-based NGS panel would fit into
the traditional CDxs scheme. While a CDx may uniquely position
the drug in the marketplace, the overarching reason for developing
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FIGURE 4 | Coordination of drug and device development for a successful companion diagnostic submission. Drug companies and diagnostic
developers may work together in several different cost sharing and assay development landmark payment formats for the development of the final IVD product.
a CDx is because it is required for the drug approval. The current
FDA guidance dictates that if the test is necessary for the safe and
effective use of the drug, then a co-Dx is required. The key factor
to determining whether a CDx is required is the efficacy of the
drug in a biomarker negative population. If efficacy in the bio-
marker negative population is sufficient for drug approval, then
a CDx may not be required, at least for an initial approval. Thus,
this question should be answered early in drug development (12,
109). It appears that NGS-based CDxs will be more relevant in the
near future in certain oncology indications where genetically tar-
geted therapies are currently prevalent, such as lung cancer, breast
cancer, and colorectal cancer.
DRUG DEVELOPMENT CHALLENGE 2 – USE A SINGLE-GENE ASSAY OR
MULTI-GENE PANEL?
At one level, the question seems to challenge one of the guiding
principles of Dx development: the simpler the better. Analytical
validation of a multi-gene assay, as discussion elsewhere in this
article, will undeniably be more work than validation of a sin-
gle gene. Yet, it might be necessary to consider the pursuit of the
multi-transcript or multi-gene panel in some cases such as if the
predictive biomarker is a set of mutations in the genes on the panel,
i.e., if the marker is a signature for response rather than a single
Dx gene mutation. The multi-gene panel approach is predicated
on two assumptions: (1) that the FDA will permit the sponsor
to mask data from genes that are not required for safe and effec-
tive use of the companion therapeutic, and (2) that the FDA will
permit different levels of rigor in the validation of genes on the
panel, based on whether they are necessary for safe and effective
use of the companion therapeutic. The authors firmly believe that
the multi-gene panel is a step toward the “multi-gene Dx/many
drugs” model even though the path there is not obvious. One of
the reasons that the change from “one-drug/one-gene Dx” model
to the “multi-gene Dx/many drugs” model will be so disruptive is
that the test results from a multiplexed panel could actually lead
to the use of a competitor’s drug. This leads to the next challenge
of how best to design clinical studies to best take advantage of all
the content on the NGS assay.
DRUG DEVELOPMENT CHALLENGE 3 – OPTIMAL TRIAL DESIGN FOR
NGS-BASED DIAGNOSTICS?
By definition precision medicine focuses on a subpopulation of
patients expected to respond to a given therapeutic. Sometimes the
population can be quite small, as in the case of metastatic lung can-
cer patients with the ALK gene fusion, for which crizotinib is indi-
cated (112, 113). Only about 5% of lung cancer patients have the
ALK gene fusion (113, 114), which means a great deal of screening
was required to identify and enroll patients in the crizotinib stud-
ies. This was very inefficient compared to a “basket trial” design
(115) in which patients are screened simultaneously for a large
number of genetic aberrations using a multi-gene panel to deter-
mine their eligibility for a large number of clinical trials involving
different therapeutic interventions. Some forward-looking models
in this area propose a multi-institution collaboration that employs
a multi-gene panel assay in which the cost of the screening assay
(including validation) is shared by different drug development
entities (49, 115, 116). While this approach would significantly
reduce the cost of screening patients for rare subpopulations of
patients in PhII and PhIII trials for each individual company, it
presents the equally interesting question of whether drug devel-
opers will collaborate with competitors in such basket trials. The
Friends of Cancer Research initiative for enrollment of patients
with advanced NSCLC into trials matched by their tumor profile
is one of the first examples of this kind of study (49). The trial
seeks to utilize a NGS panel-based approach for enrolling patients
into the most suitable trial using an adaptive trial design that
allocates patients to suitable drugs from different pharmaceutical
participants. It includes five drugs from five different companies
and will employ the FM NGS-based panel assay to guide subject
assignment and is expected to launch in spring 2014 (116). Over-
all, drug developers and Dx companies will have to work together
to navigate this disorderly transition in testing paradigm (12).
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DRUG DEVELOPMENT CHALLENGE 4 – WHEN TO COMMIT TO
CO-DIAGNOSTIC DEVELOPMENT?
An important question arises as to when the pharmaceutical com-
pany should invest in the NGS co-Dx development process. The
best guidance would dictate that CDx assay development must
begin at least 18–24 months prior to the start of the registrational
studies to allow sufficient time for development of the IUO assay
for demonstration of clinical utility in the registrational trial. The
Dx development plan depends on many factors such as complexity
of the assay, cost of pre-investment, strength of the data confirming
the biomarker hypothesis, as well as timeline of drug registration
(e.g., whether a traditional Phase 2 to Phase 3 transition timeline
is expected) (117). Therefore, variation to the ideal development
timeline is often observed and drug companies and Dx developers
utilize different developmental strategies to develop the final IVD
product with significant investment by both parties (Figure 4).
Development of a CDx test typically links the market uptake and
return on investment of Dx device to the performance of the com-
panion drug in pivotal clinical trials. As a consequence, the cost
of development may require creative cost sharing and milestone
payment agreements between the pharmaceutical and Dx part-
ner. Some of the plausible developmental strategies possible for
current NGS-based Dxs may be summarized as follows:
(i) Linear, risk-averse development model: in this model, devel-
opment proceeds by a linear, logical flow, minimizing invest-
ment risk by delaying decisions as long as possible. CDx
development is only begun after the need for a CDx is
unequivocally established or until after initial data show the
therapeutic has efficacy. Although avoiding pre-investment
in Dx development until it is clearly needed may appear to be
wise, in reality this may be a poor strategy because once it is
clear that the drug is effective, there will be a great urgency to
initiate the pivotal studies. The second aspect of risk aversion
is the desire to avoid a bridging strategy for the Dx, i.e., start-
ing the Ph3 studies with CTA instead of an IVD-ready version
of the Dx (i.e., the IUO version of the assay) and then transi-
tioning, i.e., bridging, to the IUO version by re-analyzing all
(or nearly all) of the samples on the IUO version of the assay.
This transition introduces significant risk into the process, so
avoiding bridging is a good plan, but the cost is a significant
delay in the start of the pivotal trial.
(ii) Pre-investment model: the Dx partnership is finalized and
the IVD assay development starts prior to the initiation of the
Phase 2 study, allowing sufficient time for development of the
IUO assay to be completed prior to the Phase 3 start. In this
case, the Dx development risk is low, but the Dx utility and
therapeutic development risks are high. This is because the
Dx development starts before the therapeutic is shown to be
effective and before the Dx is shown to be required. Thus, the
key risks are the uncertainty of biomarker’s clinical utility and
the therapeutic’s clinical efficacy from Phase 2 data. Although
the therapeutic sponsor partner may essentially partially fund
Dx development as part of the Dx agreement, the therapeutic
sponsor does not absorb all the risk. Dx companies have lim-
ited resources and have to select partnerships most likely to
lead to a successful Dx product launch. In other words, one
of the risks felt by the Dx company is opportunity cost if the
program is canceled for any reason, including the failure of
the therapeutic.
(iii) Bridging strategy+ partial pre-investment. In cases where
the traditional 18–24-month window for pivotal trial start
is not possible, this model may be utilized to allow a piv-
otal trial start in a timely manner. This is a very expensive
strategy with the drug sponsor absorbing most of the risk.
IVD assay developments starts with a prototype assay (non-
NGS or NGS-based) and bridging studies proceed as soon
as an IUO version of NGS-based assay is ready. This strat-
egy suffers from having high sample requirements as well as
necessitating sample stability studies.
DRUG DEVELOPMENT CHALLENGE 5 – TYPE OF A CDx DEVICE: LDT
OR KIT?
Many of the early leaders in precision medicine, realizing the pos-
sible complexity of the traditional PMA regulatory path for CDx
kit development, may consider the LDT IVD model for their ther-
apeutic that requires an in vitro Dx. This scenario could arise if
the drug maker wants to avoid a large upfront investment in a
CDx effort and has identified a reliable partner that can develop
an acceptable assay, support clinical trials and provide worldwide
access to the assay in their laboratory. The LDT route might also
be selected if the company only recognizes it needs an IVD late in
clinical development (i.e., in PhII) and wants to avoid a bridging
strategy. Even though an LDT can receive FDA-clearance through
the 510(k) process (118, 119), it seems likely that the FDA would
require the LDT to go through the PMA process. Thus, the main
advantage of the LDT route would be to avoid investment in a
traditional kit and to avoid a delay related to the development of
the IUO device. The current debate on stricter regulation of LDTs
may play an important role in such decisions (75 FR 34463, 2010).
Variability in LDT design and the increase in number of LDTs over
510(k)-cleared Dx devices is a growing concern (14), since it would
take enormous efforts to standardize LDTs to achieve universally
accepted tests. Standardization and strict regulation of CLIA NGS
LDTs may be the practical scenario encountered most in next few
years. As the FDA’s guidance and recommendations for LDT reg-
ulation become clear and start getting enforced, the clinical NGS
field will see standardization at many diverse levels, e.g., controls
used in assays, reagents/panels, assay QC parameters and rules
for accepting or failing data, bioinformatics pipelines and bio-
statistics modules, interpretation of data, reporting of data, etc.
Key considerations must include early adoption of the Dx assay,
preferably prior to pivotal studies. As discussed under time line
constraints and in Figure 4, not many current NGS-based assays
are suitable as Dxs or are ready to be developed into a regulated Dx.
DRUG DEVELOPMENT CHALLENGE 6 – HOW SHOULD CLINICAL
ACTIONABILITY BE DEFINED?
While detection of low frequency mutations is one of the
great promises of a NGS-based Dx, detection of very low fre-
quency mutations in a Dx test requires several serious design
considerations as well. For example, even if a test is technically
able to detect a very low frequency mutation (e.g.,<1%), the pres-
ence of the mutation may not correlate with therapeutic response
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since the majority of the tumor (>99%) ultimately does not carry
the said mutation. In this case, reporting of the detected mutation
may require special consideration. For example, if the said muta-
tion were present at 5% allele frequency, the Dx might report the
mutation present and qualify the patient for treatment with the
paired pharmaceutical, but if at 0.5%, it might not. In other words,
a scenario is possible where patients with a low frequency muta-
tion detected by a Dx test may be ineligible for a clinical trial due
to mutation frequency actionability thresholds (41, 120). How-
ever, while not “pharmacologically” actionable, the 0.5% mutation
detected would likely require reporting for follow-up. Ultimately
clinical utility of low frequency mutations will be demonstrated
by clinical response, which will provide clarity on what level of
sensitivity of mutation detection is acceptable for drug labeling.
Similarly, tumor heterogeneity may reveal mutations in a gene or
transcriptional changes that are not yet clinically actionable.
DRUG DEVELOPMENT CHALLENGE 7 – WHAT IS THE EX-US
REGULATORY ENVIRONMENT FOR NGS DIAGNOSTICS?
In some situations, the Dx that supports approval of a drug out-
side of the US will be different than the assay that is approved
by FDA. This can be due to a number of factors including the
US testing being a lab-based assay or the readiness of the Dx
company to support distribution worldwide. Additionally, it is
particularly important that the policies governing genetic data
collection, reporting, and analysis be clear from the start of a Dx
program in a territory. In the EU for example, a CDx is not specif-
ically formally classified, though the regulations may change soon
(121). However, the test must be CE marked under the EU IVDs
Directive (122, 123). The clinical trial use of the test can then be
included in the label following a European Commission approval.
DIAGNOSTIC DEVELOPMENT CHALLENGE 1 – ADDITIONAL
REGULATORY GUIDANCE
Through the MiSeqDx decision summary, Dx companies are just
now getting a glimpse into FDA thinking regarding NGS technol-
ogy and the use of multi-gene panels. The FDA has indicated that a
guidance on regulated NGS assays is due in 2014 and has proposed
that individual companies request early pre-submission meetings
with the Agency to discuss Dx development plans and trial design.
It is encouraging that FDA officials have offered at public forums
personal opinions that convey the Agency’s enthusiasm about the
technology and its application for therapy, as well as the recog-
nition of the inevitability of usage of NGS-based tests in public
health (focr.org). The FDA has encouraged early and open dialog
on the NGS CDx process and has implied that the process, in spite
of its complexity, is likely to be facilitated in a manner as similar
as possible to that done for existing complex Dx assays.
DIAGNOSTIC DEVELOPMENT CHALLENGE 2 – COMPETITION
FROM LDTs
The current environment is one in which NGS-based lab-
developed tests are rapidly gaining popularity in the healthcare
community and the growing use of NGS-based cancer genome
profiling may be pushing the community toward a fast adoption
of NGS-based tests. Although there are several sets of guide-
lines and recommendations (CLIA, CAP, and state guidances)
(43, 44) describing the validation and use of existing NGS LDTs,
the FDA has indicated that regulation may be necessary to stop
the growth of less rigorously validated assays and to reduce the
risk to patients. The oncology community’s clamor for an infor-
mation rich NGS Dx is possibly similar to the initial excitement
around using microarrays as Dxs, with the goal of having a sin-
gle comprehensive test that captures a large amount of relevant
content. Tests that identify patients that benefit, or not bene-
fit, from certain treatments represent new opportunities and a
new market for some companies. Many different types of com-
panies are building research usage only (RUO) cancer panels
in the expectation that they could be adopted as LDTs. Other
companies are setting up laboratories or expanding their cur-
rent laboratory capabilities to offer LDT cancer panels and other
NGS-based tests (47, 124). The latter represent a significant threat
for Dx companies and may make them hesitant to invest heav-
ily in developing an FDA-approved Dx product, especially as less
regulated LDTs continue to increase their segment of the Dx mar-
ket. For example, the recently FDA-approved molecular Dx BRAF
V600E test was followed by the development and rapid uptake of
cheaper LDTs. FDA recently issued a guidance document (Distri-
bution of IVD Products labeled for Research Use Only or IUO)
which may address some of the issues with RUO marketing in
particular.
DIAGNOSTIC COMPANY CHALLENGE 3 – LDT VERSUS IVD KIT
CONSIDERATIONS
Both LDTs and kit-based Dxs are considered to be in vitro Dxs
by the FDA, and either can go through the PMA process. Thus,
one of the major decisions for NGS-based Dxs developers will
be choosing between development of a LDT (currently working
under enforcement discretion from FDA regulation) or a commer-
cialized kit-based FDA-approved product. In this context drug
companies can choose to partner with “traditional Dx compa-
nies” which do not work with a LDT model (they don’t have or
want a CLIA service lab) or with “Lab-focused Dxs companies”
which have a CLIA service lab and that could potentially offer an
LDT-based Dx.
Currently, the NGS-based genetic tests on the market are all
CLIA/CAP-regulated lab-developed tests (11). To date, none of
these tests have been cleared or approved through FDA’s strin-
gent pre-marketing review process, which verifies the performance
claims of the test. To date only a very small number of molecular
genetic tests have FDA approval for marketing as CDxs. Examples
of FDA-approved kitted CDxs are the Roche COBAS 4800 test
for BRAF V600E mutation detection as a CDx for vemurafenib
(Zelboraf) and the Abbott Vysis ALK Break Apart FISH Probe
test to identify ALK-positive NSCLC patients for Pfizer’s approved
NSCLC therapy Xalkori (Crizotinib) (108, 109, 113, 125). There
is a separate class of lab-based, FDA-cleared IVDs, e.g., the Agen-
dia MammaPrint assay (126) and the XDx AlloMap assay (127).
The largest class of genetic tests is currently unregulated clinical
lab-developed tests. Clinical labs are overseen and regulated by the
Centers for Medicare and Medicaid Services (CMS) with the CLIA
certification process (40). Lab-developed test markets have grown
mainly because the FDA approval process is time-consuming and
very expensive (117). The extensive clinical validation and design
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control requirements expected in FDA-regulated IVD products
are deterring many companies from submitting their NGS-based
tests for the IVD process. At the same time, valid concerns about
the lack of regulatory oversight that allows tremendous variability
in test results from LDTs have led to a call for stricter regulation
of the LDT (14). The FDA has sought more involvement in LDT
regulation for a while now and there is increasing indication that
LDT regulation will be on FDA’s agenda as evident in FDA’s Guid-
ance on Personalized Medicine from October 2013. In 2010, FDA
announced plans to expand its regulation to lab-developed genetic
tests. This announcement led to heated debate within the indus-
try (117). While this is yet to happen, it may impact the clinical
LDT format of NGS assays should they become a specific CDx that
requires FDA clearance or approval.
CONCLUDING THOUGHTS
We have provided a summary of the practical challenges to the
widespread adoption of NGS-based CTAs and their further devel-
opment as CDxs. For some challenges we suggested possible reme-
dies that alleviate some of these concerns; for others we framed the
relevant questions from a stakeholder’s perspective.
It is certain that despite the challenges, in the near future NGS-
based Dxs will be a major component of the highly remunerative
personalized medicine and Dx industry. What was said about
genome sequencing may also be true for clinical NGS-based Dx
testing: that we may be overestimating the impact in the short run
but we are probably underestimating the impact in the long run
(original quote is attributed to renowned futurist Roy Amara). It
is a certainty that the healthcare system will be transformed if the
technology is embraced and implemented into clinical practice
with its full potential. We project that a variety of NGS Dx asso-
ciated companies or specializations will see exponential growth as
they aid the simplification of NGS in the clinic, especially those
that offer easy-to-use clinical interpretation interfaces or EMR
data incorporation methodologies. It is also foreseeable that clin-
ical NGS will be coupled with methods for minimally invasive
monitoring utilizing bio-fluid-based assays instead of traditional
tissue biopsies. It is also notable that as pharmaceutical companies
and healthcare systems drive clinical NGS into practice, several
models for global collaboration between pharmaceutical compa-
nies may arise which can help the field of personalized medicine
move forward exponentially.
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